Edwards Lifesciences Corp (EW) : Partner Investment Management reduced its stake in Edwards Lifesciences Corp by 12.09% during the most recent quarter end. The investment management company now holds a total of 20,654 shares of Edwards Lifesciences Corp which is valued at $2,346,294 after selling 2,840 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Edwards Lifesciences Corp makes up approximately 4.23% of Partner Investment Management’s portfolio.
Other Hedge Funds, Including , Clough Capital Partners L P sold out all of its stake in EW during the most recent quarter. The investment firm sold 38,200 shares of EW which is valued $4,339,520. Raveneur Investment Group Lp sold out all of its stake in EW during the most recent quarter. The investment firm sold 2,158 shares of EW which is valued $245,149.Tributary Capital Management reduced its stake in EW by selling 400 shares or 1.44% in the most recent quarter. The Hedge Fund company now holds 27,400 shares of EW which is valued at $3,121,408. Edwards Lifesciences Corp makes up approx 0.43% of Tributary Capital Management’s portfolio.Bnp Paribas Investment Partners S.a. boosted its stake in EW in the latest quarter, The investment management firm added 52,056 additional shares and now holds a total of 527,969 shares of Edwards Lifesciences Corp which is valued at $60,146,228. Edwards Lifesciences Corp makes up approx 0.51% of Bnp Paribas Investment Partners S.a.’s portfolio.Welch Forbes reduced its stake in EW by selling 31 shares or 0.03% in the most recent quarter. The Hedge Fund company now holds 118,519 shares of EW which is valued at $13,435,314. Edwards Lifesciences Corp makes up approx 0.40% of Welch Forbes’s portfolio.
Edwards Lifesciences Corp opened for trading at $115.5 and hit $115.985 on the upside on Thursday, eventually ending the session at $115.87, with a gain of 0.62% or 0.71 points. The heightened volatility saw the trading volume jump to 10,97,907 shares. Company has a market cap of $24,666 M.
On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 115 from a previous price target of $100 .Company shares were Reiterated by Canaccord Genuity on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 140 from a previous price target of $132 .Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.